TORONTO -- (MARKET WIRE) -- February 01, 2007 -- Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that it has entered into a Phase II clinical trial using its novel peptide vaccine in breast cancer patients in conjunction with the United States Military Cancer Institute’s (USMCI) Clinical Trials Group under a Clinical Trial Agreement. The immunotherapeutic vaccine, AE37, is being developed by Generex’s Antigen Express division in the United States.
